Small molecule drug candidates designed to address the underlying causes of disease.
For patients with idiopathic pulmonary fibrosis (IPF), chronic pain, multiple sclerosis (MS) and depression, this means targeting the specific mechanisms that cause disease progression. Ultimately, by breaking the cycle of inflammation and degeneration in these conditions, we aim to slow or even halt disease activity.
Pipeline
LPA1R Antagonist
IPF
Wholly-owned
Preclinical
Phase 1
Phase 2
Phase 3
LPA1R Antagonist
Progressive MS (PrMS)
Wholly-owned
Preclinical
Phase 1
Phase 2
Phase 3
LPA1R Antagonist
Chronic Pain
Wholly-owned
Preclinical
Phase 1
Phase 2
Phase 3
LPA1R Antagonist
Peripheral
Wholly-owned
Preclinical
Phase 1
Phase 2
Phase 3
M1R Antagonist
Relapsing-Remitting MS (RRMS)
In collaboration with Johnson & Johnson
Preclinical
Phase 1
Phase 2
Phase 3
M1R Antagonist
Major Depressive Disorder
In collaboration with Johnson & Johnson
Preclinical
Phase 1
Phase 2
Phase 3
Calpain Inhibitor
Undisclosed
Wholly-owned
Preclinical
Phase 1
Phase 2
Phase 3
Pipe-791
IPF – Our lead drug candidate, PIPE-791, targets the lysophosphatidic acid 1 receptor (LPA1R), a clinically validated target for IPF. There are estimated to be approximately 130,000 people in the United States with IPF. LPA1R antagonism is a clinically validated mechanism, and we believe that our preclinical studies and early clinical trials support the continued development of PIPE-791 for IPF.
PrMS – We are pursuing clinical development of PIPE-791 in Progressive MS (PrMS) to address the significant unmet need for a therapy that has the potential to reduce neuroinflammation and support remyelination. We believe PIPE-791 has strong biological rationale to be a potentially novel treatment for PrMS.
Chronic Pain – PIPE-791 may provide a potentially differentiated non-opioid treatment for patients by modifying the maladaptive changes associated with chronic pain.
CTX-343
We are leveraging our drug discovery capabilities to develop additional drug candidates that are synergistic with our existing portfolio. We recently commenced preclinical studies for CTX-343, a peripherally-restricted (unable to access the central nervous system) LPA1R antagonist.
PIPE-307
PIPE-307 targets the M1 muscarinic receptor (M1R), a clinically validated target in depression and relapsing-remitting multiple sclerosis (RRMS). We are developing PIPE-307 in collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.
Calpain
Calpain is a cysteine protease that requires calcium for activation. Inappropriate regulation of the calpain-calpastatin proteolytic system is implicated in a range of significant human pathological processes.